請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28367完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江文章(Wenchang Chiang) | |
| dc.contributor.author | Hsuanfei Huang | en |
| dc.contributor.author | 黃萱斐 | zh_TW |
| dc.date.accessioned | 2021-06-13T00:06:15Z | - |
| dc.date.available | 2012-07-30 | |
| dc.date.copyright | 2007-07-30 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-30 | |
| dc.identifier.citation | ATCC. 2007. American Type Culture Collection. The global bioresource center. (http://www.atcc.org/) accessed on November, 2006.
Aoki M, Tuzihara N. 1984. Effects of the hatomugi (Coix lachryma-jobi L. var. ma-yuen) on the blood pressure, cholesterol absorption and serum lipids level. Kaseigaku Zasshi 35: 89-96 Babich H, Visiolo F. 2003. In vitro cytotoxicity to human cells in culture of some phenolics from olive oil. Il Farmaco 58: 403-407. Baird, JK. 1999. A generalized statement of the law of mass action. J Chem Educ 76: 1146. Barret JM, Etievant C, Hill BT. 2000. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45: 471-476. Barret JM, Kruczynski A, Etievant C, Hill BT. 2002. Synergistic effects of F 11782, a novel dual inhibitor of toposiomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 49: 479-486. Bertino JR, Chou TC. 1997. Chemotherapy: synergism and antagonism. In: Encyclopedia of Cancer. Vol I. San Diego, California: Academic Press, Inc. pp.368-379. Budman DR, Calabro A, Kreis W. 2002. Synergistic and antagonistic combinations of drugs in human prostate cancer lines in vitro. Anticancer Drugs 13: 1011-1016. Burnstein MJ. 1993. Dietary factors related to colorectal neoplasms. Surg Clin North Am 73:13-29. Chang HC, Huang YC, Hung WC. 2003. Antiproliferative and chemopreventive effects of adlay seed on lung cancer in vitro and in vivo. J Agric Food Chem 51: 3656-3660. Chou TC. 1974. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 10: 235-274. Chou TC. 1976. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59: 253-276. Chou TC. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego, California: Academic Press, Inc. pp. 61-102. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation for synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681. Chou TC, Rideout DC. 1991. Synergism, antagonism, and potentiation in chemotherapy: an overview. In Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego, California: Academic Press, Inc. pp. 25-50. Chou TC, Talalay P. 1981. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216. Chou TC, Talalay P. 1983. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 144: 450-454. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. Chou TC, Martin N. 2004. CompuSyn. Paramus, New Jersey, USA: ComboSyn, Inc. Department of Health, Executive Branch of Taiwan. 2006. Statistics of causes of death. Vol 1. Taipei, Taiwan. Dest V M. 2000. Lung cancer. RN 63:32-34. Duke, J.A. 1992. Handbook of phytochemical constituents of GRAS herbs and other economic plants. CRC Press. Boca Raton. Florida. Fahy DM, O’Callaghan, O’Brien NM. 2004. Phytosterols: lack of cytotoxicity but interference with β-carotene uptake in Caco-2 cells in culture. Food Add Contamin 21: 42-51. Ferguson LR, Zhu ST, Harris PJ. 2005. Antioxidant and antigenotoxic effects of plant cell wall hydroxycinnamic acids in cultured HT-29 cells. Mol Nutr Food Res 49: 585-693. Frei E, Eder JP. 2003. Principles of dose, schedule, and combination therapy. In: Kufe D, Pollock R, Weichselbaum R, Bast R, Grnsler T, Holland J, Frei E, editors. Cancer medicine. 6th ed. Hamilton, Canada: BC Decker, Inc. Fulzele SV, Chatterijee A, Shaik MS, Jackson T, Ichite N, Singh M. 2007. 15-Deoxy-12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 18: 65-78. Gemma A, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H, Kudoh S. 2006. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer 6: 174-180. Han JS, Rhee AH, Cheigh HS. 1988. Changes of lipid in raw and processed adlay powder during storage. Korean J Food Soc Technol 20:691-698. Hewlett PS, Plackett RL. 1979. The interpretation of quantal responses in biology. 1st Ed. Baltimore, Maryland: University Park Press. pp. 12-21. Ho CC. 2000. Effect of dehulled adlay on lipid and carbohydrate metabolism in STZ-induced diabetic rats. Master’s Thesis of department of food science of National Taiwan Ocean University. Keelung, Taiwan. Hsia SM, Chiang W, Kuo YH, Wang PS. 2006. Downregulation of progesterone biosynthesis in rat granulosa cells by adlay (Coix lachrymal-jobi L. var. ma-yuen Stapf.) bran extracts. Int J Impot Res 18: 264-274. Hsu HY. 1986. Oriental Materia Medica- a concise guide. 1st Ed. Long Beach, CA, USA: Oriental Healing Arts Institute. pp.280-281. Hsu HY, Lin BF, Lin JY, Kuo CC, Chiang W. 2003. Suppression of allergic reactions by dehulled adlay in association with the balance of Th1/Th2 cell responses. J Agric Food Chem 51: 3763-3769. Hung WC and Chang HC. 2003. Methanolic extract of adlay seed suppress COX-2 expression of human lung cancer cells via inhibition of gene transcription. J Agric Food Chem 51: 7333-7337. Iwai K, Kishimoto N, Kakino Y, Mochida K, Fujita T. 2004. In vitro antioxidative effects and tyrosinase inhibitory activities of seven hydroxycinnamoyl derivatives in green coffee beans. J Agric food Chem 52: 4893-4898. Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, Phillips PC. 1998. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs 9: 641-652. Kau YC, Hung YC, Zizza AM, Zurakowski D, Greco WR, Wang GK, Gerner P. 2006. Efficacy of lidocaine or bupivacaine combined with ephedrine in rat sciatic nerve block. Reg Anesth Pain Med 31: 14-18. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi KI. 1998. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42: 91-98. Keys JD. 1987. Chinese Herbs-their botany, chemistry, and pharmacodynamics. 4th Ed. Tokyo, Japan: Charles E. Tuttle Company, Inc. pp.45-47. Kim IY. 2006. Improving outcomes with chemotherapy in colorectal cancer: current options, current evidence. J Korean Soc Coloproctol 22: 137-148. Kukongviriyapan V, Phromsopha N, Tassaneeyakul W, Kukongviriyapan U, Sripa B, Hahnvajanawong V, Bhudhisawasdi. 2006. Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Xenobiotica 36: 15-28. Kuo CC, Shih MC, Kuo YH, Chiang W. 2001. Antagonism of free-radical induced damage of adlay seed and its antiproliferative effect in human histolytic lymphoma U937 monocytic cells. J Agric Food Chem 49: 1564-1570. Kuo CC, Chiang W, Liu GP, Chien YL, Lee CK, Lo JM, Huang SL, Shih MC, Kuw YH. 2002. 2,2’-Diphenyl-1-picrylhydrazyl radical-scavenging active components from adlay (Coix lachryma-jobi L. Var. ma-yuen Stapf) hulls. J Agric Food Chem 50: 5850-855. Lee RA, Kim HA, Kang BY, Kim KH. 2006. Hemoglobin induces colon cancer cell proliferation by release of reactive oxygen species. World J Gastroenterol 12: 5644-5650. Li SS, Gao Z, Feng X, Jones SH, Hecht SM. 2004. Plant sterols as selective DNA polymerase β lyase inhibitors and potentiantors of bleomycin cytotoxicity. Bioorgan Med Chem 12: 4253-4258. Loewe S. 1957. Antagonism and antagonists. Pharmacol Rev 9: 237-242. Loewe S, Aldous RA, Fox SR, Johnson DG, Perkins W. 1954. Isobols of dose-effect relations in the combination of pentyleneterazole and trimethadione. J Pharmacol Exp Ther 113: 475-480. Ma J, Maliepaard M, Nooter K, Boersma AWM, Verseij J, Stoter G, Schellens JHM. 1998. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41: 307-316. Martinez-Irujo JJ, Villahermosa ML, Alberdi E, Santiago E. 1996. A chalkboard method to evaluate interactions between drugs. Biochem Pharmacol 51: 635-644. Martins de Lima T, Cury-Boaventura MF, Giannocco G, Nunes MT, Curi R. 2006. Comparative toxicity of fatty acids on a macrophage cell line (J774). Clin Sci 111: 307-317. Minna JD. 2005. Neoplasms of the lung. In Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, and Isselbacher KJ, editors. Harrison's Principles of Internal Medicine. 16th ed. USA: the McGraw-Hill Companies, Inc. p. 506. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. Nagao T, Otsuka H, Kohda H, Sato T, Yamaski K. 1985. Benzoxazinones from Coix lachrymal-jobi L var. ma-yuen. Phytochem 24: 2959-2962. Nam NH, Kim HM, Bae KH, Ahn BZ. 2003. Inhibitory effects of Vietnamese medicinal plants on tube-like formation of human umbilical venous cells. Phytother Res 17:107-111. Numata M, Yamamoto A, Moribayashi A, Yamada H. 1994. Antitumor components isolated from the Chinese herbal medicine Coix lachryma-jobi. Planta Medica 60: 356-359. Otsuka H, Hirai Y, Nagao T, Yamaski K. 1988. Anti-inflammatory activity of benzoxaninoids from roots of Coix lachryma-jobi L. var. ma-yuen. J Natu Prod 51:73-79. Ramos RR, Alarcon-Aguilar F, Lara-lemus A, Flores-Saenz JL. 1992. Hypoglycemic effect of plants used in Mexico as antidiabetics. Archives Med Res 23: 59-64. Shih CK, Chiang W, Kuo ML. 2004. Effects of adlay on azoxymethane-induced colon carcinogenesis in rats. Food Chem Toxicol 42:1339-1347. Simone JV. 1979. Childhood leukemia as a model for cancer research. Cancer Res 39: 4301-4307. Stuart RGA. 1911. Chinese Materia Medica- vegetable kingdom. Shainghai, China: the American Presbyterian Mission Press. p. 122. Takahashi M, Konno C, Hikino H. 1986. Isolation and hypoglycemic activity of coixan A, B, C, glycans of Coix lachryma-jobi var. ma-yuen seed. Planta Med. 52:63-65. Tanimura A. 1961. Studies on the anti-tumor component in the seeds of Coix lachryma-jobi L. var. mayuen (Roman.) Stapf. II. The structure of coixenolide. Chem Pharm Bull 9: 47-53. Tokuda H, Matsumoto T, Konoshima T, Kozuka M, Nishino H, Iwashima A. 1990. Inhibitory effects on Epstein-Barr virus activation and anti-tumor promoting activities of coix seed. Planta Medica 56: 653-654. Ukita T, Tanimura A. 1961. Browning reaction products produced by the reaction between sugars and amino acids. VII. Decomposition of lipid hydroperoxide by the browning products. Nippon Shokuhin Kogyo Gakkaishi 15: 187-191. Webb JL. 1963. Effect of more than one inhibitor. In: Enzymes and metabolic inhibitors. Vol 1. 2nd ed. New York: Academic Press. p. 66-79 & 487-512. Weinstein JN, Bunow b, Weislow OS, Schinazi RF, Wahl SM, Wahl LM, Szebeni J. 1990. Synergistic drug combinations in AIDS therapy: dipyridamole-3’-azido-3’-deoxythymidine in particular and principles of analysis in general. Ann N Y Acad Sci 616: 367-384. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28367 | - |
| dc.description.abstract | 在過去二十年間，癌症一直是台灣十大死亡病因之一，其中肺癌和結腸癌更居十大癌症的第一和第三位。本研究以組合指數(combination index)來探討由本實驗室自薏苡麩皮甲醇萃出物分中所分離純化出之化學有效成分對抑制人類肺癌A549和結腸癌細胞HT-29生長的相乘作用或拮抗作用，探討各個活性成分之間的相互影響和作用關係。由兩種化合物組合的結果發現，咖啡酸(caffeic acid；PA4)或3-O-coumaroyl-β-sitosterol (PE1)與其他化合物組合時，對於抑制A549細胞增生方面有相乘的作用，另一方面，綠原酸(chlorogenic acid；PA6)與其他化合物組合時，有強烈的拮抗作用。而在抑制HT-29細胞增生方面，棕櫚酸(palmitic acid；FA )、5-hydroxy-7-methoxy-4’-acetylisoflavone (IF) 和豆脂醇(stigmasterol；S1)的兩兩組合間皆有相乘的作用。在這些純化合物中，細胞毒性會隨著試驗細胞的不同而產生不一樣的效果，所以組合時所產生的效力也不同。例如，PA4可與其他化合物產生抑制A549細胞增生的相乘效果，但在抑制HT-29細胞增生方面，PA4與IF或FA的組合則有拮抗的效果。由三種化合物組合的結果發現，PA4-PE1-IF組合 與 PA6-PE1-FA組合皆有最強抑制A549細胞增生的效果，而在抑制HT-29細胞增生方面，S1-IF-FA為最強相乘作用之組合。另外，PA4-PA6-IF組合皆對此兩種癌細胞有最強的拮抗作用。最後，在設計開發薏仁成為輔助抑制腫瘤保健食品時，須要針對不同的細胞來做不同的設計，以提高抑制癌細胞生長的效果。 | zh_TW |
| dc.description.abstract | The malignant tumor has continuously occupied the first place of the top ten leading causes of death for more than twenty years in Taiwan. Among those malignant neoplasm cases, the lung cancer and colorectal cancer are the first and third places of the top ten leading cancer, respectively. In this study, the combination index methodology was used to discuss the synergism or antagonism among these anti-tumor components from adlay bran. The result showed that caffeic acid (PA4) and 3-O-coumaroyl-β-sitosterol (PE1) appeared to be most synergistic compounds for combining with other compounds and chlorogenic acid (PA6) was the most antagonistic compound with other compounds on the growth inhibition of A549, a human lung cancer cell line; while any 2-compound combinations of palmitic acid (FA), 5-hydroxy-7-methoxy- 4’-acetylisoflavone (IF) and stigmasterol (S1) appeared to be synergistic on the growth inhibition HT-29, a human colorectal cancer cell line. Moreover, the cytotoxicity of compounds varied depending on the cell line tested and that such variation may in turn influence those effects of compound combinations. For example, in 2-compound combinations, PA4 exerted synergism when combining with other compounds to inhibit the growth of A549; while it became an antagonist toward other compounds, such as IF and FA, to inhibit the growth of HT-29. Moreover, in 3-compound combinations, the most synergistic 3-compound groups were PA4-PE1-IF and PA6-PE1-FA against A549 growth; while the most synergistic group was S1-IF-FA against HT-29 growth. On the other hand, the combination of PA4, PA6, and IF was the most antagonism on the growth inhibition of A549 and HT-29. From both cell lines, the results of the 3-compound combinations could be explained by the results of the 2-compound combinations. Last, the design of anti-cancer adlay supplement must be tumor-specific since that the cytotoxicity of the compounds varies depending on the cell line tested and that such variation may in turn influence those combined effects of the pure compounds. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T00:06:15Z (GMT). No. of bitstreams: 1 ntu-96-R94641012-1.pdf: 1085854 bytes, checksum: b1dd188a4ee269df3ec7e56c064ab27e (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 論文口試委員審定書…………………………………………………i
謝誌(Acknowledgement)……………………………………………ii Chinese abstract…………………………………………………iii English abstract………………………………………………… iv Table of Contents……………………………………………… vi List of Tables…………………………………………………… x List of Figures………………………………………………… xi List of Symbols and Abbreviations………………………… xiii Chapter 1. Introduction……………………………………… 1 Chapter 2. Background………………………………………… 3 2.1 Drug combination and interaction……………………… 3 2.1.1 Reasons of drug combination………………………… 3 2.1.2 Mechanisms of drug interaction……………………… 4 2.1.3 Examples of drug combination………………………… 6 2.1.4 Three major methods to determine drug interaction…7 2.1.4.1 Fractional product method of Webb……………………7 2.1.4.2 Classical isobologram method of Loewe………………8 2.1.4.3 Combination index method of Chou and Talalay……10 2.2 Methods for dose-effect analysis…………………………13 2.2.1 Empirical curve-fitting and read-off…………………13 2.2.2 Linearity method……………………………………………14 2.2.3 Empirical formula method…………………………………14 2.2.4 Method of the Median-effect principle……………… 15 2.3 Cancers……………………………………………………… 19 2.3.1 Epidemiology of the cancer…………………………… 19 2.3.2 Lung cancer………………………………………………19 2.3.3 Colorectal cancer…………………………………………20 2.4 Adlay……………………………………………………………21 2.4.1 General information………………………………………21 2.4.2 Structures of adlay………………………………………21 2.4.3 Composition of adlay…………………………………… 22 2.4.4 Physiological functions of adlay…………………… 23 2.4.4.1 Blood sugar regulation……………………………… 24 2.4.4.2 Blood pressure regulation……………………………24 2.4.4.3 Anti-oxidation………………………………………… 24 2.4.4.4 Anti-inflammation………………………………………24 2.4.4.5 Immune regulation………………………………………25 2.4.4.6 Regulation of ovulatory activity………………… 25 2.4.4.7 Prevention and cure of cancer………………………25 2.4.5 Adlay and cancers…………………………………………26 2.4.5.1 Adlay and lung cancer…………………………………26 2.4.5.2 Adlay and colon cancer……………………………… 26 2.5 Pure compounds derived from adlay bran……………… 27 Chapter 3. Objective…………………………………………… 33 Chapter 4. Experimental design……………………………… 35 Chapter 5. Materials and methods…………………………… 37 5.1 Materials………………………………………………………37 5.1.1 The 17 pure compounds tested………………………… 37 5.1.2 Experimental compounds………………………………… 38 5.1.3 Equipments………………………………………………… 39 5.1.4 Cell culture supplies……………………………………39 5.1.5 Graphical software………………………………………40 5.1.6 Cell lines…………………………………………………40 5.1.6.1 A549 human lung cancer cell line………………… 41 5.1.6.2 HT-29 human colorectal cancer cell line…………41 5.1.6.3 Maintenance of cell lines……………………………42 5.1.6.4 Cryopreservation of cell lines…………………… 43 5.1.6.5 Defrost of cell lines…………………………………44 5.2 Methods…………………………………………………………44 5.2.1 Sample preparation……………………………………… 44 5.2.2 MTT assay……………………………………………………45 5.2.2.1 Theory…………………………………………………… 45 5.2.2.2 Protocol………………………………………………… 46 5.2.3 Combination of pure compounds…………………………47 5.2.3 Statistical analysis…………………………………… 49 Chapter 6. Results and discussion……………………………50 6.1 Cell viability test on 17 pure compounds…………… 50 6.1.1 Effect of 17 pure compounds on the growth of A549…50 6.1.2 Effect of 17 pure compounds on the growth of T29…53 6.2 The combination effect of the five most potent pure compounds…56 6.2.1 The combination effect on A549………………56 6.2.1.1 Determination of the combination ratio on A549…56 6.2.1.2 The interaction of the combined compounds on A549…64 6.2.2 The combination effect on HT29………………………74 6.2.2.1 Determination of the combination ratio on HT-29…74 6.2.2.2 The interaction of the combined compounds on HT-29…81 6.3 Overall discussion……………………………………90 Chapter 7. Conclusions……………………………………………93 References……………………………………………………………95 Appendices…………………………………………………………105 Appendix A………………………………………………………105 Appendix B………………………………………………………106 Appendix C…………………………………………………………109 Appendix D……………………………………………………… 110 | |
| dc.language.iso | en | |
| dc.subject | 中間效應方程式 | zh_TW |
| dc.subject | 相乘作用 | zh_TW |
| dc.subject | 組合指數 | zh_TW |
| dc.subject | 拮抗作用 | zh_TW |
| dc.subject | 薏苡麩皮 | zh_TW |
| dc.subject | Adlay bran | en |
| dc.subject | the median-effect principle | en |
| dc.subject | antagonism | en |
| dc.subject | synergism | en |
| dc.subject | combination index | en |
| dc.title | 利用組合指數探討薏苡麩皮中抑制肺癌及結腸癌物質間之相互作用 | zh_TW |
| dc.title | The Investigation on the Interaction among Anti-tumor Compounds derived from Adlay Bran against Human Lung and Colorectal Cancer Cells using Combination Index Methodology | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 龔瑞林(Richard Zwe-Ling Kong),劉仁沛(Jen-Pei Liu),孫璐西(Lucy Sun Hwang),沈立言 | |
| dc.subject.keyword | 組合指數,相乘作用,拮抗作用,中間效應方程式,薏苡麩皮, | zh_TW |
| dc.subject.keyword | Adlay bran,combination index,synergism,antagonism,the median-effect principle, | en |
| dc.relation.page | 112 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-30 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| 顯示於系所單位： | 食品科技研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 1.06 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。